Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Frontiers in Medicine
|
July 12, 2021
Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study
Beatriz Sicilia, Lara Arias, Gadea Hontoria, et al.
Gastroenterologia Y Hepatologia
|
February 21, 2022
Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up
Ester Badia Aranda, Cristina Fernández Marcos, Aida Puebla Maestu, et al.
Gastroenterologia Y Hepatologia
|
September 11, 2021
Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection
Judith Gómez Camarero, Ester Badia Aranda, Raisa Quiñones Castro, et al.
European Journal of Gastroenterology & Hepatology
|
December 5, 2015
Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy
Federico Sáez-Royuela, Pedro Linares, Luis A Cervera, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics
|
May 24, 2017
Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
Huascar Ramos, Pedro Linares, Ester Badia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 31, 2018
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Marc Puigvehí, Beatriz De Cuenca, Ana Viu, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Carlos Fernández Carrillo, Sabela Lens, Elba Llop, et al.
Journal of Hepatology
|
June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Alimentary Pharmacology & Therapeutics
|
May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Hepatology (Baltimore, Md.)
|
March 5, 2024
Recurrent alcohol-associated hepatitis is common and is associated with increased mortality
Jordi Gratacós-Ginès, Pilar Ruz-Zafra, Miriam Celada-Sendino, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Frontiers in Medicine
|
July 12, 2021
Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study
Beatriz Sicilia, Lara Arias, Gadea Hontoria, et al.
Gastroenterologia Y Hepatologia
|
February 21, 2022
Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up
Ester Badia Aranda, Cristina Fernández Marcos, Aida Puebla Maestu, et al.
Gastroenterologia Y Hepatologia
|
September 11, 2021
Hepatitis B and C screening in hospitalized patients with SARS-CoV-2 infection
Judith Gómez Camarero, Ester Badia Aranda, Raisa Quiñones Castro, et al.
European Journal of Gastroenterology & Hepatology
|
December 5, 2015
Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy
Federico Sáez-Royuela, Pedro Linares, Luis A Cervera, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics
|
May 24, 2017
Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
Huascar Ramos, Pedro Linares, Ester Badia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 31, 2018
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Marc Puigvehí, Beatriz De Cuenca, Ana Viu, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Carlos Fernández Carrillo, Sabela Lens, Elba Llop, et al.
Journal of Hepatology
|
June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Alimentary Pharmacology & Therapeutics
|
May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.
Hepatology (Baltimore, Md.)
|
March 5, 2024
Recurrent alcohol-associated hepatitis is common and is associated with increased mortality
Jordi Gratacós-Ginès, Pilar Ruz-Zafra, Miriam Celada-Sendino, et al.
Page
of 2